Ferric carboxymaltose is an iron replacement therapy used to treat iron deficiency anemia in children and adults with intolerance or inadequate clinical response to oral iron, and in adult patients who have non-dialysis dependent chronic kidney disease. It was FDA approved on July 25, 2013.
- Mechanism
- Curator reviewed · 1 reference
Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.
- Primary indication
- Ferric carboxymaltose is an iron replacement product indicated for the treatment of iron deficiency anemia in patients ≥1 year of age who have an intolerance to, or unsatisfactory response from, oral iron therapy, and in...Curator reviewed · 4 structured indications
- First approval
- Canada, 2024 · United States, 2013
- Also known as
- Iron carboxymaltose · Iron dextri-maltose
- Code names
- VIT 45
- Brand names
Resolves to
Clinical / RWD
What you can answer from here — as of August 09, 2026
Which other approved drugs treat the same conditions as Ferric carboxymaltose, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account